$- Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia$

January 26, 2023

MarketScreener

Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

(marketscreener.com) Bristol Myers Squibb today announced topline results from TRANSCEND CLL 004, a P... See more »

January 25, 2023Nasdaq

Amgen is Oversold

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stock... See more »

January 25, 2023centralcharts

Allergan Aesthetics takes a 360approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023

Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outc... See more »

January 25, 2023Medthority

HSR clearance for expansion of Innate Pharma collaboration with Sanofi on NK cell engagers

Innate Pharma SA announced the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Ant... See more »

January 25, 2023Medical Device Network

Thermo Fisher Scientific and AstraZeneca partner to develop new CDx test

The new CDx test will identify NSCLC patients who could be eligible to receive treatment with Tagriss... See more »

January 24, 2023Markets Insider

Bayer's contrast agent Ultravist gets approval in EU for use in breast cancer detection

Bayer (BAYZF) (BAYRY) said on Monday that its iodine-based contrast agent Ultravist-300, -370 was app... See more »

January 25, 2023Endpoints News

Novartis re-enlists spokescelebrity Ken Jeong for Xiidra movie trailer spoof campaign

Pharma marketers are known for recruiting both doctors and celebrities for ad campaigns. But Novartis... See more »

January 25, 2023

STAT News

STAT+: Pharmalittle: Merck ends late-stage trial for Keytruda in prostate cancer; doctor group says 60 Minutes segment on Wegovy was an ad

Merck is discontinuing a trial of Keytruda in prostate cancer after interim data showed it was unlike... See more »

January 26, 2023

Medical Device Network

Roche and TIB Molbiol develop new PCR test to detect Omicron sub-variant

The VirSNiP SARS-CoV-2 Spike F486P test targets the unique F486P mutation found in the XBB.1.5 Omicro... See more »

January 26, 2023

MarketScreener

Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

(marketscreener.com) Bristol Myers Squibb today announced topline results from TRANSCEND CLL 004, a P... See more »

January 25, 2023Nasdaq

Amgen is Oversold

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stock... See more »

January 25, 2023centralcharts

Allergan Aesthetics takes a 360approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023

Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outc... See more »

January 25, 2023Medthority

Followers on Owler

37,809

Annual Revenue

$96B

Employees

144,000

Chairman & CEO

Joaquin Duato

CEO Approval Rating

95/100

Johnson & Johnson is a New Jersey-based firm that engages in research, manufacturing and sale of healthcare products including consumer, pharmaceutical and medical devices.

See Johnson & Johnson company profile »

Stay up-to-date with the latest news on Johnson & Johnson